摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Cyclopropyl-6-[4-(4-fluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine

中文名称
——
中文别名
——
英文名称
3-Cyclopropyl-6-[4-(4-fluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
英文别名
Triazolopyridine oxazole inhibitor 46;5-(3-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-4-(4-fluorophenyl)-1,3-oxazole
3-Cyclopropyl-6-[4-(4-fluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine化学式
CAS
——
化学式
C18H13FN4O
mdl
——
分子量
320.326
InChiKey
HTRYISKMFSYGKQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    56.2
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • Novel triazolo-pyridines anti-inflammatory compounds
    申请人:Pfizer Inc.
    公开号:US20030096838A1
    公开(公告)日:2003-05-22
    The present invention relates to novel triazolo-pyridines of the formula I 1 wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R 2 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; R 3 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明涉及公式I1的新型三唑并[3,4-d]吡啶化合物,其中Het是一个含有1-2个异原子(氮、和氧)的可选取代的5-元杂环,其中至少一个异原子必须是氮;R2选自氢,(C1-C6)烷基或其他适当的取代基;R3选自氢,(C1-C6)烷基或其他适当的取代基;s是0-5的整数;本发明还涉及其制备中间体、含有它们的制药组合物及其医药用途。本发明的化合物是MAP激酶,特别是p38激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、脑卒中或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病中有用。
  • TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS
    申请人:Pfizer Products Inc.
    公开号:EP1370559A1
    公开(公告)日:2003-12-17
  • US6696464B2
    申请人:——
    公开号:US6696464B2
    公开(公告)日:2004-02-24
  • [EN] TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS<br/>[FR] TRIAZOLOPYRIDINES, AGENTS ANTI-INFLAMMATOIRES
    申请人:PFIZER PROD INC
    公开号:WO2002072579A1
    公开(公告)日:2002-09-19
    The present invention relates to novel triazolo-pyridines of the formula I wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R2 is selected from the group consisting of hydrogen, (C¿1?-C6) alkyl or other suitable substituents; R?3¿ is selected from the group consisting of hydrogen, (C¿1?-C6)alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
查看更多